Biphasic effects of MPP+, a possible parkinsonism inducer, on dopamine content and tyrosine hydroxylase mRNA expression in PC12 cells

https://doi.org/10.1016/0197-0186(94)00122-BGet rights and content

Abstract

When PC 12 cells were treated with 1-methyl-4-phenylpyridinium ion (MPP+) at various concentrations for 1 week, the dopamine (DA) content was increased compared to the control at 1–30 μM but was decreased to less than the control at concentrations above 100 μM. Cell death was caused by 300 μM MPP+, indicating that decrease in DA content proceeds cell death. When the cells were treated with 100 μM MPP+ for various periods, DA content was transiently increased (6 h-2 days) and then gradually decreased below the control (4–7 days). These results suggest that MPP+ possesses biphasic effects on DA content, being dependent on both concentrations and treatment periods. Moreover, by treatment with 100 μM MPP+, tyrosine hydroxylase (TH) mRNA expression was also transiently increased and then gradually decreased below the control, suggesting that MPP+ also possesses biphasic effects on TH mRNA expression.

Reference (31)

  • BeckK.D. et al.

    Tyrosine hydroxylase mRNA expression by dopaminergic neurons in culture: effect of I-methyl-4-phenylpyridinium treatment

    J. Neurochem.

    (1991)
  • BurnsR.S. et al.

    A primate model of parkinsonism : selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

  • BuuN.T.

    Uptake of 1-methyl-4-phenylpyridinium and dopamine in the mouse brain cell nuclei

    J. Neurochem.

    (1993)
  • D'AmatoR.J. et al.

    Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin

    Science

    (1986)
  • D'AmatoR.J. et al.

    Characterization of the binding of N-methyl-4-phenyl-pyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanine

    J. Neurochem.

    (1987)
  • Cited by (11)

    • Discovery of a novel neuroprotectant, BHDPC, that protects against MPP<sup>+</sup>/MPTP-induced neuronal death in multiple experimental models

      2015, Free Radical Biology and Medicine
      Citation Excerpt :

      Mitochondrial complex I deficiency is one of the major clinical changes in PD patients, pointing toward a critical role of MPP+/MPTP in elucidating the possible pathogenesis mechanisms of neurodegenerative diseases [10,11]. In addition, the neurotoxicity and mechanisms of MPP+/MPTP have been well defined in various models [12–14]. Therefore, MPP+/MPTP-induced neurotoxicity in vitro and in vivo has been commonly used to evaluate neuroprotective candidates [15–17].

    View all citing articles on Scopus
    View full text